 |
| Artificial Pancreas Device System (APDS) Market |
Eating habits of
type 1 diabetes patients is highly curtailed, complemented by regular
administration of insulin. Type 1 diabetes patients require multiple
doses of insulin in a day and all-round the year. Advancements in
research and technology has led to commercialization of easy-to-us
insulin delivery systems such as insulin pens, pumps, inhaled
insulin, and injectors. Use of syringes to deliver insulin has become
obsolete with the introduction of advanced and easy-to-use insulin
delivery systems mentioned above. Moreover, these systems offer the
convenience to self-administer insulin at home. An artificial
pancreas is a novel concept that promises to revolutionize the entire
diabetes market. The system automatically detects glucose level in
patient’s blood or plasma and accordingly administers the necessary
dosage of insulin. Medtronic’s MiniMed 670G is one such wearable
artificial pancreas. The system is automated to monitor glucose
levels and deliver insulin through an insulin pump attached to the
system. The artificial
pancreas system comprises a transmitter, sensor, and
insulin pump. This helps in continuous monitoring and diabetes
management at ease.
Available
Exclusive Sample Copy of This Report @
https://www.coherentmarketinsights.com/insight/request-sample/79
Market
Dynamics:
The artificial
pancreas device system (APDS) market growth would be mainly driven by
increasing adoption of the highly useful systems the large base of
diabetes type 1 patients, further supplemented by ever increasing
incidence of type 1 diabetes. According to the World Health
Organization (WHO), number of diabetes patients worldwide increased
from 108 million in 1980 to 422 million in 2014. According to
Juvenile Diabetes Research Foundation (JDRF), there were around 1.5
million type 1 diabetics worldwide in 2015. JDRF funds research in
diabetes 1 and the non-profit organization expected the first
artificial pancreas to be commercialized in 2017. According to the
Center for Disease Control and Prevention (CDC), type 1 diabetes
accounts for around 5% of the total diagnosed diabetes cases in
adults in the U.S. Developed regions are expected to dominate the
artificial pancreas device system (APDS) market size, as these
regions are early adopters of disruptive technologies. With the
introduction of this technology, market for insulin pens and
injectors is expected to be impacted negatively.
Market
Taxonomy:
This report segments
the global artificial pancreas device system (APDS) market on the
basis of technology, distribution channel, end user and geography. On
the basis of technology, the global artificial pancreas device system
(APDS) market is categorized into Treat to Range/Control to Range
(TTR/CTR), Treat to Target/ Control to Target (TTR/CTT) and Threshold
Suspended Device Systems. On the basis of distribution channel the
global artificial pancreas device system (APDS) market is segmented
into e-commerce, Standalone Retail Shops and hospitals. End user of
the APDS include type 1 and type 2 diabetic patients. For
comprehensive understanding of market dynamics, the global artificial
pancreas device system (APDS) market is analyzed across key
geographical regions namely North America, Europe, Asia Pacific,
Latin America, Africa, and Middle East. Each of these regions is
analyzed on basis of market findings across major countries in these
regions for a macro-level understanding of the market.
Technological
advancements to drive growth of the global artificial pancreas device
system (APDS) market
In 2016, the U.S.
FDA approved a hybrid closed-loop artificial pancreas device system
(APDS) MiniMed 670G which is an automated system. The continuous
glucose monitor in the system automatically sends signals to the
insulin pump to deliver insulin when the glucose level in body goes
beyond the acceptable limit. Thus, there is no need for the user to
stimulate the release of insulin every time the glucose level is
abnormal. This provide the user freedom to perform his/her daily
activities. Such advancement in T1D management is expected to be
highly preferred by the users and medical community, leading to
higher advocacy to use this device especially among the patient group
using insulin pumps. Moreover, in mid-2018, a study will test a
bihormonal “bionic pancreas” system at the Massachusetts General
Hospital (Boston) and Boston University. This would further fuel the
artificial pancreas device system (APDS) market growth and attract
more investments.
Key players
operating in the global Artificial Pancreas Device System (APDS)
market:
• Medtronic
• Medtrum
• Tandem Diabetes
Care, Inc.
• Johnson &
Johnson
• Beta Bionics
• Bigfoot
Biomedical
• Insulet
Corporation
Detailed
Segmentation:
Global
Artificial Pancreas Device System (APDS) Market, By Technology:
• Threshold
Suspended Device Systems
• Treat to
Range/Control to Range (TTR/CTR)
• Treat to Target/
Control to Target (TTR/CTT)
Global
Artificial Pancreas Device System (APDS) Market, By Distribution
Channel:
• E-commerce
• Standalone
Retail Shops
• Hospitals
Global
Artificial Pancreas Device System (APDS) Market, By End User:
• Type 1 Diabetic
Patients
• Type 2 Diabetic
Patients
Global
Artificial Pancreas Device System (APDS) Market, By Geography:
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East
• Africa
Grab Your
Report at an Impressive Discount @
https://www.coherentmarketinsights.com/insight/request-discount/79
About Coherent
Market Insights:
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market
Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
0 comments:
Post a Comment